AllerGene’s approach uses targeted lipid nanoparticles to deliver short-lived mRNA to immune cells, enabling the body to temporarily generate CAR-T cells in vivo. These CAR-T cells can transmit inhibitory signals to safely and selectively remove mast cells, the central drivers of allergic and anaphylactic reactions. As new, non-sensitized mast cells naturally regenerate, the immune system resets—without permanent genetic changes.
A T cell can kill mast cells via apoptosis, a controlled self-destruction that shrinks the cell, forms membrane blebs (balloon-like protrusions) that encapsulate internal contents, and fragments into “apoptotic bodies,” preventing inflammation and leakage of internal granules such as histamine, unlike messy necrosis, where contents spill out. T cells trigger this through either perforin/granzyme (creating pores for granzymes to enter and activate caspases) or Fas/FasL (receptor-ligand binding), both activating executioner caspases that dismantle the cell from within, resulting in tidy removal by phagocytosis.
The World’s Most Comprehensive AI Engine for Research and Development Insights
Ask a research question and compare answers from Claude, ChatGPT, Gemini, DeepSeek, xAI and more – with sources.
